BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20874822)

  • 21. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
    Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
    Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas.
    Lee SW; Nam SY; Im KC; Kim JS; Choi EK; Ahn SD; Park SH; Kim SY; Lee BJ; Kim JH
    Radiother Oncol; 2008 May; 87(2):211-6. PubMed ID: 18237806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) uptake measured by positron emission tomography is associated with reduced overall survival in patients with oral squamous cell carcinoma.
    Hofele C; Freier K; Thiele OC; Haberkorn U; Buchmann I
    Oral Oncol; 2009 Nov; 45(11):963-7. PubMed ID: 19665923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.
    Manohar K; Mittal BR; Bhattacharya A; Malhotra P; Varma S
    Nucl Med Commun; 2012 Sep; 33(9):974-81. PubMed ID: 22811258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using PET-CT in the restaging of primitive mediastinal B-cell lymphoma (PMBCL) after chemotherapy: which criteria should we use?
    Giunta F; Zotta M; Menga M; Balma M; Bellò M; Passera R; Filippi AR; Chiappella A; Ladetto M; Ricardi U; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):214-9. PubMed ID: 25669764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
    Bodet-Milin C; Touzeau C; Leux C; Sahin M; Moreau A; Maisonneuve H; Morineau N; Jardel H; Moreau P; Gallazini-Crépin C; Gries P; Gressin R; Harousseau JL; Mohty M; Moreau P; Kraeber-Bodere F; Le Gouill S
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1633-42. PubMed ID: 20428863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
    Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
    J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
    Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
    Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
    Zhang Q; Tian T; Wang L; Qiu H; Li D
    Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
    Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
    Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma].
    Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.